Cardiovascular Pharmacology

SECTION 1

Historical Context & Motivation

Cardiovascular disease has been the leading cause of mortality worldwide for more than a century, and the pharmacological tools available to clinicians have evolved dramatically over that period. Early remedies relied on plant-derived preparations whose mechanisms were poorly understood, yet their clinical efficacy hinted at targetable physiological systems within the heart and vasculature. The development of cardiovascular pharmacology as a discipline is inseparable from advances in receptor biology, hemodynamic physiology, and clinical trial methodology. Understanding the historical arc of these discoveries provides critical context for why specific drug classes target specific receptors—and why board examiners expect you to know both the mechanisms and the clinical rationale behind each therapeutic choice.

1785

William Withering & Digitalis

William Withering published An Account of the Foxglove, documenting the use of digitalis (foxglove extract) for the treatment of 'dropsy' (heart failure). This landmark work established the concept that plant-derived compounds could directly modulate cardiac function.

1948

Ahlquist's Receptor Theory

Raymond Ahlquist proposed the existence of α- and β-adrenergic receptors, providing the molecular framework for understanding catecholamine signaling in the heart and vasculature. This classification paved the way for selective adrenergic blockade.

1964

Propranolol — First Beta-Blocker

Sir James Black developed propranolol, the first clinically useful β-adrenergic antagonist. His work earned the Nobel Prize in 1988 and launched an entire class of drugs essential for managing hypertension, angina, and arrhythmias.

1981

ACE Inhibitors Enter the Clinic

Captopril was approved by the FDA, becoming the first oral angiotensin-converting enzyme (ACE) inhibitor. Its development followed the study of bradykinin-potentiating peptides from Brazilian pit viper venom, illustrating how natural toxin research can yield transformative therapeutics.

1987–Present

Statins & Modern CV Pharmacology

Lovastatin became the first FDA-approved HMG-CoA reductase inhibitor, ushering in the statin era. Subsequent decades saw the introduction of ARBs, direct oral anticoagulants (DOACs), PCSK9 inhibitors, and SGLT2 inhibitors—each expanding the pharmacological toolbox for cardiovascular risk reduction.

The overarching question that cardiovascular pharmacology addresses is deceptively simple: How can we pharmacologically reduce myocardial oxygen demand, optimize vascular resistance, maintain appropriate coagulation, and correct rhythm disturbances—while minimizing adverse effects? Every drug class you will encounter in this lesson answers some component of that question, and USMLE vignettes will consistently test your ability to connect mechanism to clinical scenario.

SECTION 2

Core Principles & Drug Class Overview

Cardiovascular pharmacology can be organized around four therapeutic goals: controlling blood pressure (antihypertensives), restoring normal cardiac rhythm (antiarrhythmics), reducing myocardial ischemia (antianginals), and preventing pathological clotting or promoting necessary hemostasis (antithrombotics). Each goal engages distinct physiological targets—adrenergic receptors, ion channels, the renin-angiotensin-aldosterone system (RAAS), the coagulation cascade, and lipid metabolism. Mastering the interactions among these targets is essential, because many patients present with overlapping indications that require multi-drug regimens.

Hemodynamic Modulators

Drugs that alter cardiac output (CO) and/or systemic vascular resistance (SVR). Recall: MAP ≈ CO × SVR. Antihypertensives may target heart rate, contractility, preload, or afterload.

Ion Channel & Rhythm Agents

Antiarrhythmics classified by the Vaughan-Williams system (Classes I–IV) based on their primary ion channel target. They modulate Na⁺, K⁺, or Ca²⁺ conductances and autonomic input to restore normal sinus rhythm.

RAAS Modulators

ACE inhibitors, ARBs, direct renin inhibitors, and mineralocorticoid receptor antagonists interrupt the renin-angiotensin-aldosterone axis at different points, reducing blood pressure, volume overload, and pathological cardiac remodeling.

Antithrombotic & Lipid Agents

Antiplatelet drugs, anticoagulants, and thrombolytics address clot prevention and dissolution. Statins and other lipid-lowering agents reduce atherosclerotic plaque burden, the upstream cause of many CV events.

Inotropes & Heart Failure Agents

Positive inotropes (e.g., digoxin, dobutamine) increase contractility. Newer agents like sacubitril/valsartan (ARNI) and SGLT2 inhibitors represent a paradigm shift in heart failure management, with mortality benefit demonstrated in landmark trials.

✦ KEY TAKEAWAY

Think of the cardiovascular system as a plumbing network: the heart is the pump, the arteries are the pipes, blood is the fluid, and clots are blockages. Antihypertensives reduce pressure in the pipes (afterload) or decrease how hard the pump works (cardiac output). Antiarrhythmics fix the pump's electrical wiring. Antithrombotics prevent blockages, and lipid-lowering agents keep the pipe walls clean. Every CV drug class maps onto one of these roles.

SECTION 3

RAAS Pathway — Visual Map

The renin-angiotensin-aldosterone system (RAAS) is a central target in cardiovascular pharmacology because it simultaneously regulates blood pressure, sodium/water balance, and cardiac remodeling. The diagram below maps the enzymatic cascade from renin release to aldosterone secretion and identifies exactly where each drug class intervenes. Memorizing these intervention points is essential for Step 1 questions that ask you to predict the downstream biochemical consequences of a given drug.

The RAAS cascade begins with angiotensinogen from the liver and proceeds through enzymatic conversion by renin and ACE. Drug intervention points are shown in dashed boxes: aliskiren blocks renin, ACE inhibitors block conversion to Ang II, ARBs block the AT₁ receptor, and mineralocorticoid antagonists block aldosterone downstream.

A high-yield clinical detail: because ACE inhibitors block the degradation of bradykinin (a vasodilator and cough mediator), patients on these drugs may develop a persistent dry cough—a side effect that ARBs do not share because they act downstream at the AT₁ receptor. Angioedema, though rare, is another bradykinin-mediated adverse effect of ACE inhibitors and is a board-favorite tested scenario. Additionally, both ACE inhibitors and ARBs are teratogenic and absolutely contraindicated in pregnancy—a critical fact for any USMLE question involving a pregnant patient with hypertension.

SECTION 4

Mechanisms of Action — Deep Dive

Antihypertensive Mechanisms & Hemodynamic Equations

The fundamental hemodynamic relationship that governs blood pressure is expressed by the equation linking mean arterial pressure (MAP) to cardiac output and systemic vascular resistance. Every antihypertensive drug reduces MAP by decreasing one or both of these determinants. Beta-blockers primarily decrease cardiac output through negative chronotropy and inotropy, while calcium channel blockers (dihydropyridines) primarily reduce SVR by relaxing vascular smooth muscle. ACE inhibitors and ARBs lower both CO (via volume reduction) and SVR (via decreased angiotensin II–mediated vasoconstriction).

MEAN ARTERIAL PRESSURE

MAP = CO × SVR

MAP = mean arterial pressure (mmHg); CO = cardiac output (L/min) = HR × SV; SVR = systemic vascular resistance (dyn·s/cm⁵). Antihypertensives reduce MAP by lowering CO, SVR, or both.

CARDIAC OUTPUT

CO = HR × SV

HR = heart rate (beats/min); SV = stroke volume (mL/beat). Beta-blockers reduce HR (negative chronotropy) and contractility (thus SV), while diuretics reduce preload and therefore SV.

Vaughan-Williams Antiarrhythmic Classification

The Vaughan-Williams classification categorizes antiarrhythmic drugs by their primary electrophysiological mechanism. Class I agents block Na⁺ channels (further subdivided into Ia, Ib, Ic based on kinetics and effect on action potential duration). Class II agents are β-blockers that decrease SA and AV nodal conduction. Class III agents block K⁺ channels, prolonging repolarization and the effective refractory period (ERP). Class IV agents block L-type Ca²⁺ channels, slowing AV nodal conduction. This framework is not perfect—amiodarone, for instance, has properties spanning all four classes—but it remains the board-tested standard.

QT INTERVAL RELATIONSHIP

QTc = QT / √RR

QTc = corrected QT interval (Bazett's formula); QT = measured QT interval (sec); RR = interval between R waves (sec). Class Ia and Class III agents prolong the QT interval, increasing risk of torsades de pointes.

⚡ High-Yield Board Pearl

USMLE loves to present a patient on sotalol or quinidine who develops syncope with a rhythm strip showing polymorphic VT (torsades de pointes). The correct next step is IV magnesium and drug discontinuation. Always check the QTc when a question mentions Class Ia or III antiarrhythmics.

SECTION 5

Drug Class Breakdown & Antiarrhythmic Map

The following diagram maps the Vaughan-Williams antiarrhythmic classes to their ion channel targets, key prototype drugs, and the expected ECG changes. Studying this visual alongside the pharmacological table below will help you rapidly match a clinical vignette to the responsible drug class on board exams.

Upper panel: the four Vaughan-Williams classes with prototype drugs and ECG effects. Lower panel: a stylized ventricular action potential showing which phase each class targets. Class I acts on phase 0 (Na⁺ influx), Class III on phase 3 (K⁺ efflux), Class IV on phase 2 (Ca²⁺ influx), and Class II modulates phase 4 depolarization in pacemaker cells.

High-Yield Cardiovascular Drug Classes for USMLE Step 1

Drug Class	Mechanism	Key Side Effects	Clinical Pearls
ACE Inhibitors (lisinopril, enalapril)	Block ACE → ↓ Ang II, ↑ bradykinin	Dry cough, angioedema, hyperkalemia, teratogenicity	First-line in HFrEF, diabetic nephropathy; check K⁺ and creatinine
ARBs (losartan, valsartan)	Block AT₁ receptor directly	Hyperkalemia, teratogenicity; NO cough	Alternative to ACEi if cough intolerable; similar renal protective benefit
β-Blockers (metoprolol, carvedilol)	Block β₁ → ↓ HR, contractility, renin release	Bradycardia, bronchospasm (non-selective), mask hypoglycemia	Mortality benefit in HFrEF (carvedilol, metoprolol succinate, bisoprolol); first-line post-MI
CCBs (amlodipine, verapamil)	Block L-type Ca²⁺ channels; DHP → vasodilation; non-DHP → ↓ HR/conduction	Peripheral edema (DHP), constipation (verapamil), AV block (non-DHP)	Amlodipine safe in HF; never combine non-DHP CCB with β-blocker (risk of heart block)
Thiazide Diuretics (HCTZ, chlorthalidone)	Inhibit Na⁺/Cl⁻ symporter in DCT → ↑ Na⁺/water excretion	Hypokalemia, hyperuricemia, hypercalcemia, hyperglycemia	First-line HTN therapy (JNC 8); chlorthalidone preferred for outcome data
Loop Diuretics (furosemide, bumetanide)	Inhibit Na⁺/K⁺/2Cl⁻ transporter in thick ascending limb	Hypokalemia, ototoxicity, hypocalcemia, hypomagnesemia	DOC for acute decompensated HF; note: opposite Ca²⁺ effect vs. thiazides
Statins (atorvastatin, rosuvastatin)	Inhibit HMG-CoA reductase → ↓ hepatic cholesterol → ↑ LDL receptor expression	Myopathy/rhabdomyolysis, hepatotoxicity	Cornerstone of primary & secondary ASCVD prevention; pleiotropic anti-inflammatory effects

SECTION 6

Worked Example — Clinical Vignette

Board questions in cardiovascular pharmacology often present a clinical vignette requiring you to identify the drug, predict a side effect, or choose the next best step. Let us walk through a representative USMLE-style question step by step.

USMLE-Style Vignette: Heart Failure Management

Step 1 — Read the StemA 62-year-old man with a history of ischemic cardiomyopathy (LVEF 30%) presents for routine follow-up. He currently takes lisinopril 20 mg daily, carvedilol 25 mg BID, and furosemide 40 mg daily. His BP is 110/70 mmHg, HR 64 bpm. Labs: K⁺ = 4.2 mEq/L, Cr = 1.1 mg/dL, BNP = 450 pg/mL. He reports NYHA class II symptoms. Which medication should be added next to reduce mortality?

Step 2 — Identify the DiagnosisThe patient has heart failure with reduced ejection fraction (HFrEF), LVEF 30%, NYHA class II. He is already on guideline-directed medical therapy (GDMT) with an ACE inhibitor and a β-blocker with proven mortality benefit.

Diagnosis: HFrEF on partial GDMT

Step 3 — Recall GDMT for HFrEFThe four pillars of HFrEF therapy with mortality benefit are: (1) ACEi/ARB/ARNI, (2) β-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) mineralocorticoid receptor antagonist (MRA — spironolactone or eplerenone), and (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). The patient is on pillars 1 and 2 but is missing an MRA and an SGLT2 inhibitor.

Step 4 — Check ContraindicationsFor spironolactone/eplerenone: K⁺ must be < 5.0 mEq/L and creatinine < 2.5 mg/dL (men). The patient's K⁺ = 4.2 and Cr = 1.1, so there is no contraindication. His eGFR is adequate for SGLT2 inhibitor initiation as well (typically ≥ 20 mL/min).

Step 5 — Select the AnswerAdd spironolactone (or eplerenone). The RALES trial demonstrated a 30% relative reduction in mortality with spironolactone in patients with severe HF (NYHA III–IV), and EMPHASIS-HF showed eplerenone benefit in NYHA II. On USMLE, the MRA is the classic 'add-on' drug when ACEi + β-blocker are already in place. An SGLT2 inhibitor would also be correct (DAPA-HF, EMPEROR-Reduced), but the MRA is the more traditionally tested answer.

Answer: Add spironolactone (aldosterone antagonist)

⚠️ Monitor for Hyperkalemia

When an MRA is added to an ACE inhibitor or ARB, the risk of hyperkalemia increases significantly. Board questions often test this: if K⁺ rises above 5.5 mEq/L after adding spironolactone, the drug should be dose-reduced or discontinued. Always monitor K⁺ within 1 week of initiation.

SECTION 7

Strengths, Limitations & Key Comparisons

Each cardiovascular drug class has distinct advantages and limitations that USMLE questions exploit by placing patients in clinical scenarios where the 'usual' first-line choice is contraindicated. The ability to pivot between drug classes—knowing which alternative to reach for—is a hallmark of clinical pharmacology competence.

ACE Inhibitors vs. ARBs — Board-Tested Differences

Comparison	ACE Inhibitors	ARBs
Mechanism	Block ACE enzyme → ↓ Ang II production, ↑ bradykinin	Block AT₁ receptor → prevent Ang II action; no bradykinin effect
Cough	Yes (~15% of patients) — bradykinin-mediated	No — no effect on bradykinin degradation
Angioedema risk	Higher (bradykinin accumulation)	Lower but not zero (use with caution if prior ACEi angioedema)
Teratogenicity	Yes — renal dysgenesis, oligohydramnios	Yes — same mechanism
HFrEF data	Extensive (CONSENSUS, SOLVD, SAVE)	Strong (Val-HeFT, CHARM); valsartan in ARNI

DHP vs. Non-DHP Calcium Channel Blockers

Feature	DHP CCBs (Amlodipine)	Non-DHP CCBs (Verapamil, Diltiazem)
Primary site	Vascular smooth muscle	Cardiac muscle (SA/AV node)
Effect on HR	Reflex tachycardia (or neutral)	↓ HR (negative chronotropy/dromotropy)
Use in HF	Safe (amlodipine shown safe in PRAISE trial)	Contraindicated in systolic HF (negative inotropy)
Combine with β-blocker?	Yes (often done for HTN)	Avoid — risk of severe bradycardia / heart block

✦ KEY TAKEAWAY

Think of drug classes as tools in a toolbox: a wrench (ACEi) and a socket wrench (ARB) both loosen the same bolt (RAAS), but the socket wrench doesn't accidentally bump your knuckles (cough). The board tests whether you know when to swap tools (ACEi → ARB for cough), when NOT to combine tools (non-DHP CCB + β-blocker), and which tools have absolute contraindications (any RAAS blocker in pregnancy).

SECTION 8

Connection to Advanced Cardiovascular Therapeutics

While the foundational drug classes discussed above form the core of USMLE Step 1 cardiovascular pharmacology, an awareness of emerging therapies and advanced concepts provides important context. Several newer agents are already appearing in updated question banks, particularly sacubitril/valsartan (the angiotensin receptor-neprilysin inhibitor, ARNI), SGLT2 inhibitors (empagliflozin, dapagliflozin) for heart failure regardless of diabetes status, PCSK9 inhibitors (evolocumab, alirocumab) for refractory hyperlipidemia, and direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) that have largely replaced warfarin in atrial fibrillation.

Classic vs. Advanced Cardiovascular Agents

Classic Agent	Advanced Agent	Key Difference
ACEi / ARB alone	Sacubitril/Valsartan (ARNI)	ARNI adds neprilysin inhibition → ↑ natriuretic peptides → additional natriuresis, vasodilation, and anti-remodeling. PARADIGM-HF showed superior mortality reduction vs. enalapril in HFrEF.
Traditional HF regimen	SGLT2 Inhibitors	Originally for diabetes, now proven to reduce HF hospitalizations and CV death even in non-diabetics (DAPA-HF, EMPEROR-Reduced). Mechanism includes osmotic diuresis, reduced preload, and favorable cardiac metabolic effects.
High-dose statins	PCSK9 Inhibitors	Monoclonal antibodies that increase hepatic LDL receptor recycling → dramatic LDL reduction (~60% additional). FOURIER and ODYSSEY OUTCOMES trials showed CV event reduction.
Warfarin (VKA)	DOACs (rivaroxaban, apixaban)	Direct factor Xa or thrombin inhibitors with predictable pharmacokinetics, no INR monitoring. Preferred in non-valvular AF. Contraindicated in mechanical valve patients (use warfarin).

As you progress from Step 1 into clinical clerkships and Step 2 CK, these newer agents will become increasingly prominent. The pharmacological principles remain the same: identify the physiological target, understand the mechanism, and anticipate adverse effects. The conceptual scaffold you build now—RAAS modulation, ion channel blockade, hemostatic balance, lipid metabolism—will serve as the framework upon which all future therapeutic knowledge is layered.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A patient is started on an ACE inhibitor for hypertension. Two weeks later, she develops a persistent dry cough. She is switched to an ARB, and the cough resolves. Explain the biochemical mechanism underlying the cough with ACE inhibitors and why ARBs do not produce this effect.

PROBLEM 2 — BASIC CALCULATION

A patient's baseline mean arterial pressure (MAP) is 105 mmHg with a cardiac output (CO) of 6 L/min and a systemic vascular resistance (SVR) of 17.5 mmHg·min/L. After starting amlodipine (a DHP CCB), her SVR decreases by 20% while CO remains essentially unchanged. Calculate the new MAP and state whether this represents therapeutic efficacy.

PROBLEM 3 — INTERMEDIATE

A 58-year-old man with atrial fibrillation is placed on a rate-control regimen. His cardiologist starts metoprolol, but his ventricular rate remains 110 bpm at rest. The cardiologist considers adding either verapamil or amlodipine. Which drug should be chosen for additional rate control, and which should be avoided? Explain the pharmacological rationale.

PROBLEM 4 — APPLIED

A 70-year-old woman with HFrEF (LVEF 25%) is on lisinopril, carvedilol, spironolactone, and furosemide. She is admitted for acute decompensated heart failure. Her potassium is 5.8 mEq/L, creatinine is 2.4 mg/dL, and she is oliguric. Which medications are most likely contributing to the hyperkalemia, and what immediate pharmacological adjustments should be made?

PROBLEM 5 — CRITICAL THINKING

Amiodarone is classified as a Class III antiarrhythmic (K⁺ channel blocker) in the Vaughan-Williams system, yet it also exhibits Class I, II, and IV properties. Discuss how these multi-channel effects contribute to amiodarone's broad-spectrum antiarrhythmic efficacy, explain why it has a lower proarrhythmic risk of torsades de pointes compared to 'pure' Class III agents like sotalol despite prolonging the QT interval, and identify the major non-cardiac toxicities that limit its long-term use.

SUMMARY

Cardiovascular Pharmacology — Summary

Cardiovascular pharmacology for USMLE Step 1 centers on understanding how drug classes modulate the key determinants of cardiovascular function. Antihypertensives reduce blood pressure by lowering cardiac output (CO), systemic vascular resistance (SVR), or both—with ACE inhibitors and ARBs targeting the RAAS, β-blockers reducing adrenergic stimulation, calcium channel blockers modulating Ca²⁺-dependent vascular tone and cardiac conduction, and diuretics decreasing circulating volume. The Vaughan-Williams classification organizes antiarrhythmics by ion channel target: Class I (Na⁺), Class II (β-receptor), Class III (K⁺), and Class IV (Ca²⁺), with amiodarone spanning all four.

For heart failure (HFrEF), the four-pillar GDMT approach—ACEi/ARB/ARNI + β-blocker + MRA + SGLT2 inhibitor—has strong mortality evidence. Statins remain the cornerstone of lipid-lowering therapy via HMG-CoA reductase inhibition, while antithrombotics (antiplatelets, anticoagulants, thrombolytics) prevent and treat pathological clotting. Advanced agents—ARNI, PCSK9 inhibitors, DOACs—are increasingly board-relevant. The key to USMLE success is mapping each drug to its mechanism, knowing its high-yield side effects (ACEi cough, statin myopathy, amiodarone toxicities, drug-induced QT prolongation), and recognizing absolute contraindications (RAAS blockers in pregnancy, non-DHP CCBs in systolic HF).